MarketCap
Facebook
X
TelegramQuarterly report 2025-Q4
added 02-06-2026
Canopy Growth Corporation Shares 2011-2026 | CGC
Annual Shares Canopy Growth Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 108 M | 74.8 M | 46.4 M | 39.1 M | 372 M | 348 B | 25 | 177 M | 119 M | 77 M | 32.2 M | - | - | - | - |
All numbers in CAD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 348 B | 25 | 31.7 B |
Quarterly Shares Canopy Growth Corporation
| 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 368 M | 332 M | 205 M | 184 M | 129 M | 93.9 M | 81 M | 91.1 M | 82.9 M | - | 51.7 M | - | - | - | - | 394 M | 390 M | 389 M | - | 373 M | 372 M | 372 M | - | 349 M | 347 M | 347 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in CAD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 394 M | 51.7 M | 261 M |
Shares of other stocks in the Drug manufacturers industry
| Issuer | Shares | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AcelRx Pharmaceuticals
ACRX
|
42.4 M | - | 7.5 % | $ 6.35 M |  USA |
 |
Alimera Sciences
ALIM
|
25.6 M | - | - | $ 142 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
46.3 M | - | - | $ 754 M | USA |
 |
Agile Therapeutics
AGRX
|
2.16 M | - | 10.11 % | $ 58.2 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
150 M | - | 0.86 % | $ 117 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
12.9 M | - | -39.89 % | $ 27.7 M | USA |
 |
Aurora Cannabis
ACB
|
169 M | $ 3.44 | 3.61 % | $ 86.3 M |  Canada |
 |
Perrigo Company plc
PRGO
|
138 M | $ 9.65 | 0.16 % | $ 1.34 B | USA |
 |
Catalent
CTLT
|
181 M | - | - | $ 11.5 B | USA |
 |
Athenex
ATNX
|
6.54 M | - | -23.39 % | $ 1.76 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
95.1 M | - | - | $ 2.06 B |  France |
 |
Cronos Group
CRON
|
350 M | $ 2.64 | 2.33 % | $ 1.39 B | Canada |
 |
DURECT Corporation
DRRX
|
26.3 M | - | - | $ 50.1 M | USA |
 |
Emergent BioSolutions
EBS
|
51.2 M | - | - | $ 419 M | USA |
 |
Endo International plc
ENDP
|
235 M | - | - | $ 28.9 M |  Irlanda |
 |
Rockwell Medical
RMTI
|
23.3 M | $ 1.08 | 4.37 % | $ 25.2 M | USA |
 |
Evoke Pharma
EVOK
|
3.34 M | - | - | $ 36.6 M | USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
50.8 M | - | -0.1 % | $ 2.03 B |  Schweden |
 |
HEXO Corp.
HEXO
|
127 M | - | 2.45 % | $ 38.1 M | Canada |
 |
Cumberland Pharmaceuticals
CPIX
|
14.1 M | $ 3.32 | 6.07 % | $ 46.7 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
21.3 M | - | - | $ 193 M | Canada |
 |
Solid Biosciences
SLDB
|
87.5 M | $ 7.29 | 9.13 % | $ 638 M | USA |
 |
Sundial Growers
SNDL
|
1.86 M | $ 1.38 | 0.36 % | $ 3.37 M | Canada |
 |
Sonoma Pharmaceuticals
SNOA
|
1.24 M | $ 2.35 | 0.43 % | $ 2.92 M | USA |
 |
Bausch Health Companies
BHC
|
365 M | $ 5.13 | 2.6 % | $ 1.87 B | Canada |
 |
PetIQ
PETQ
|
29.1 M | - | 1.64 % | $ 400 M | USA |
 |
OptiNose
OPTN
|
112 M | - | - | $ 1.08 B | USA |
 |
PLx Pharma
PLXP
|
23.7 M | - | -27.8 % | $ 2.56 M | USA |
 |
ProPhase Labs
PRPH
|
15.8 M | - | - | $ 5.07 M | USA |
 |
Pacira BioSciences
PCRX
|
46.2 M | $ 23.46 | 1.12 % | $ 1.08 B | USA |
 |
Evolus
EOLS
|
64.5 M | $ 4.36 | -1.58 % | $ 281 M | USA |
 |
Radius Health
RDUS
|
47.2 M | - | - | $ 1.42 B | USA |
 |
Relmada Therapeutics
RLMD
|
39.5 M | $ 6.66 | 9.18 % | $ 263 M | USA |
 |
Tilray
TLRY
|
618 M | $ 6.95 | 4.35 % | $ 4.29 B | Canada |
 |
Veru
VERU
|
135 M | $ 2.31 | 0.87 % | $ 312 M | USA |
 |
OrganiGram Holdings
OGI
|
256 M | $ 1.38 | 2.99 % | $ 402 M | Canada |
 |
SCYNEXIS
SCYX
|
49.9 M | $ 0.9 | 0.11 % | $ 44.9 M | USA |
 |
Jupiter Wellness
JUPW
|
54.4 M | - | - | $ 33.6 M | USA |
 |
Viatris
VTRS
|
1.2 B | $ 13.65 | 2.13 % | $ 16.4 B | USA |
 |
China Pharma Holdings
CPHI
|
17.5 M | $ 0.6 | 6.3 % | $ 10.5 M |  China |
 |
Assertio Holdings
ASRT
|
6.4 M | $ 18.31 | 10.9 % | $ 117 M | USA |
 |
Lannett Company
LCI
|
40.4 M | - | 1.15 % | $ 7.11 M | USA |
 |
cbdMD
YCBD
|
4.31 M | - | - | $ 3.32 M | USA |
 |
Organogenesis Holdings
ORGO
|
132 M | $ 2.44 | 1.04 % | $ 321 M | USA |
 |
Harrow Health
HROW
|
36.8 M | $ 36.62 | 4.02 % | $ 1.35 B | USA |
 |
TherapeuticsMD
TXMD
|
10.4 M | $ 2.33 | 1.53 % | $ 24.3 M | USA |
 |
Recro Pharma
REPH
|
95.2 M | - | -4.76 % | $ 65.3 M | USA |
 |
Tricida
TCDA
|
51.3 M | - | - | $ 3.25 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
42.7 M | - | - | $ 55.5 M | USA |